Shopping Cart
- Remove All
- Your shopping cart is currently empty
ER-50891 is a potent retinoic acid receptor alpha (RARα) antagonist. er-50891 reduces the inhibitory effect of allosteric retinoic acid and restores osteoblast differentiation induced by bone morphogenetic protein 2.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $163 | In Stock | |
5 mg | $438 | In Stock | |
10 mg | $578 | In Stock | |
25 mg | $927 | In Stock | |
50 mg | $1,260 | In Stock | |
100 mg | $1,680 | In Stock | |
200 mg | $2,270 | In Stock |
Description | ER-50891 is a potent retinoic acid receptor alpha (RARα) antagonist. er-50891 reduces the inhibitory effect of allosteric retinoic acid and restores osteoblast differentiation induced by bone morphogenetic protein 2. |
In vitro | ER-50891 significantly antagonized the inhibition of ATRA and enhanced the total cell metabolic activity and proliferation of preosteoblasts. Dose-dependent assays show ER-50891 could also rescue ATRA inhibited OCN expression and mineralization with or without the induction of BMP. ER-50891 also suppressed the ALP activity that was synergistically enhanced by BMP and ATRA. Neither ATRA, nor ER-50891 or their combination significantly affected the level of BMP-induced phosphorylated Smad1/5. The antagonist of RARα, ER-50891 could significantly attenuate ATRA's inhibitive effects on BMP 2-induced osteoblastogenesis.[3] |
Molecular Weight | 432.51 |
Formula | C29H24N2O2 |
Cas No. | 187400-85-7 |
Smiles | C(C)(C)C=1C2=C(C(=CC(=N2)C=3NC(=CC3)C4=CC=C(C(O)=O)C=C4)C5=CC=CC=C5)C=CC1 |
Relative Density. | 1.223 g/cm3 (Predicted) |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||
Solubility Information | DMSO: 10 mg/mL (23.12 mM), Sonication is recommended. | |||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.